vs
LIGAND PHARMACEUTICALS INC（LGND）与Resolute Holdings Management, Inc.（RHLD）财务数据对比。点击上方公司名可切换其他公司
Resolute Holdings Management, Inc.的季度营收约是LIGAND PHARMACEUTICALS INC的2.0倍（$117.7M vs $59.7M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs -1.5%，领先76.5%），Resolute Holdings Management, Inc.自由现金流更多（$189.2M vs $45.9M）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
Resolute Holdings Management, Inc.是一家澳大利亚矿业企业，核心业务布局于非洲地区，目前运营两座金矿，分别为位于马里的 Syama 金矿和塞内加尔的 Mako 金矿，专注于黄金资源的勘探、开采及相关运营管理工作。
LGND vs RHLD — 直观对比
营收规模更大
RHLD
是对方的2.0倍
$59.7M
净利率更高
LGND
高出76.5%
-1.5%
自由现金流更多
RHLD
多$143.3M
$45.9M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $117.7M |
| 净利润 | $44.8M | $-1.7M |
| 毛利率 | — | 55.7% |
| 营业利润率 | 23.2% | 30.2% |
| 净利率 | 75.1% | -1.5% |
| 营收同比 | 39.4% | — |
| 净利润同比 | 244.1% | — |
| 每股收益（稀释后） | $2.42 | $-0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LGNDRHLD
| Q4 25 | $59.7M | $117.7M | ||
| Q3 25 | $115.5M | $120.9M | ||
| Q2 25 | $47.6M | $119.6M | ||
| Q1 25 | $45.3M | $103.9M | ||
| Q4 24 | $42.8M | — | ||
| Q3 24 | $51.8M | — | ||
| Q2 24 | $41.5M | — | ||
| Q1 24 | $31.0M | — |
净利润LGNDRHLD
| Q4 25 | $44.8M | $-1.7M | ||
| Q3 25 | $117.3M | $-231.0K | ||
| Q2 25 | $4.8M | $-611.0K | ||
| Q1 25 | $-42.5M | $-3.4M | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-7.2M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $86.1M | — |
毛利率LGNDRHLD
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 57.5% | ||
| Q1 25 | — | 52.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率LGNDRHLD
| Q4 25 | 23.2% | 30.2% | ||
| Q3 25 | 47.6% | 34.3% | ||
| Q2 25 | 17.7% | 34.0% | ||
| Q1 25 | -79.9% | 24.7% | ||
| Q4 24 | -22.5% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | -46.0% | — | ||
| Q1 24 | 9.6% | — |
净利率LGNDRHLD
| Q4 25 | 75.1% | -1.5% | ||
| Q3 25 | 101.6% | -0.2% | ||
| Q2 25 | 10.2% | -0.5% | ||
| Q1 25 | -93.6% | -3.2% | ||
| Q4 24 | -72.6% | — | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | -125.0% | — | ||
| Q1 24 | 278.1% | — |
每股收益（稀释后）LGNDRHLD
| Q4 25 | $2.42 | $-0.20 | ||
| Q3 25 | $5.68 | $-0.03 | ||
| Q2 25 | $0.24 | $-0.07 | ||
| Q1 25 | $-2.21 | $-0.39 | ||
| Q4 24 | $-1.70 | — | ||
| Q3 24 | $-0.39 | — | ||
| Q2 24 | $-2.88 | — | ||
| Q1 24 | $4.75 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $205.5M |
| 总债务越低越好 | — | $169.8M |
| 股东权益账面价值 | $1.0B | $6.5M |
| 总资产 | $1.6B | $333.4M |
| 负债/权益比越低杠杆越低 | — | 26.03× |
8季度趋势，按日历期对齐
现金及短期投资LGNDRHLD
| Q4 25 | $733.5M | $205.5M | ||
| Q3 25 | $664.5M | $148.0M | ||
| Q2 25 | $245.0M | $99.9M | ||
| Q1 25 | $208.9M | $71.0M | ||
| Q4 24 | $256.2M | — | ||
| Q3 24 | $219.6M | — | ||
| Q2 24 | $226.9M | — | ||
| Q1 24 | $310.6M | — |
总债务LGNDRHLD
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益LGNDRHLD
| Q4 25 | $1.0B | $6.5M | ||
| Q3 25 | $950.2M | $10.8M | ||
| Q2 25 | $828.5M | $9.6M | ||
| Q1 25 | $795.5M | $8.9M | ||
| Q4 24 | $830.4M | — | ||
| Q3 24 | $841.2M | — | ||
| Q2 24 | $775.2M | — | ||
| Q1 24 | $806.5M | — |
总资产LGNDRHLD
| Q4 25 | $1.6B | $333.4M | ||
| Q3 25 | $1.5B | $293.2M | ||
| Q2 25 | $948.6M | $253.3M | ||
| Q1 25 | $905.4M | $214.3M | ||
| Q4 24 | $941.8M | — | ||
| Q3 24 | $954.9M | — | ||
| Q2 24 | $866.4M | — | ||
| Q1 24 | $913.9M | — |
负债/权益比LGNDRHLD
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $196.1M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $189.2M |
| 自由现金流率自由现金流/营收 | 76.9% | 160.8% |
| 资本支出强度资本支出/营收 | 0.0% | 5.8% |
| 现金转化率经营现金流/净利润 | 1.03× | — |
| 过去12个月自由现金流最近4个季度 | $48.9M | $313.2M |
8季度趋势，按日历期对齐
经营现金流LGNDRHLD
| Q4 25 | $45.9M | $196.1M | ||
| Q3 25 | $13.1M | $59.6M | ||
| Q2 25 | $15.8M | $48.9M | ||
| Q1 25 | $-25.4M | $18.4M | ||
| Q4 24 | $28.5M | — | ||
| Q3 24 | $36.5M | — | ||
| Q2 24 | $13.3M | — | ||
| Q1 24 | $18.7M | — |
自由现金流LGNDRHLD
| Q4 25 | $45.9M | $189.2M | ||
| Q3 25 | $13.1M | $58.6M | ||
| Q2 25 | $15.6M | $47.5M | ||
| Q1 25 | $-25.7M | $17.8M | ||
| Q4 24 | $27.8M | — | ||
| Q3 24 | $35.9M | — | ||
| Q2 24 | $12.9M | — | ||
| Q1 24 | $18.6M | — |
自由现金流率LGNDRHLD
| Q4 25 | 76.9% | 160.8% | ||
| Q3 25 | 11.3% | 48.5% | ||
| Q2 25 | 32.7% | 39.7% | ||
| Q1 25 | -56.6% | 17.1% | ||
| Q4 24 | 64.8% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 31.1% | — | ||
| Q1 24 | 60.1% | — |
资本支出强度LGNDRHLD
| Q4 25 | 0.0% | 5.8% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.4% | 1.2% | ||
| Q1 25 | 0.5% | 0.6% | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.3% | — |
现金转化率LGNDRHLD
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 3.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RHLD
暂无分部数据
